Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice

Diabetes and Metabolism

Volumn 41, Issue 5, 2015, Pages 425-428

  Nonogaki, K ^a   Kaji, T ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

5 HT1B receptor agonist; Alogliptin; DPP 4; GLP 1; MCPP

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 5 PROPOXY 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDINE; ALOGLIPTIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; SODIUM CHLORIDE; 1-(3-CHLOROPHENYL)PIPERAZINE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, MOUSE; HTR1B PROTEIN, MOUSE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN 1B RECEPTOR; URACIL;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEEDING; FOOD DEPRIVATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL STIMULATION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; FOOD DRUG INTERACTION; GENETICS; GLUCOSE INTOLERANCE; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; SECRETION (PROCESS); UPREGULATION;

ADMINISTRATION, ORAL; ANIMALS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOOD-DRUG INTERACTIONS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; INJECTIONS, INTRAPERITONEAL; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE, INBRED C57BL; PIPERAZINES; PIPERIDINES; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN 5-HT1 RECEPTOR AGONISTS; UP-REGULATION; URACIL;

EID: 84947043968     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2015.06.005     Document Type: Article

References (12)

1. Heisler L.K., Cowley M.A., Tecott L.H., Fan W., Low M.J., Smart J.L., et al. Activation of central melanocortin pathways by fenfluramine. Science 2002, 297:609-611.
2. Lee M.D., Somerville E.M., Kennett G.A., Dourish C.T., Clifton P.G. Reduced hypophagic effects of d-fenfluramine and the 5-HT2C receptor agonist mCPP in 5-HT1B receptor knockout mice. Psychopharmacology (Berl) 2004, 176:39-49.
3. y mice. Endocrinology 2006, 147:5893-5900.
4. Nonogaki K., Nozue K., Takahashi Y., Yamashita N., Hiraoka S., Kumano H., et al. Fluvoxamine, a selective serotonin reuptake inhibitor, and 5-HT2C receptor inactivation induce appetite-suppressing effects in mice via 5-HT1B receptors. Int J Neuropsychopharmacol 2007, 5:675-681.
5. Nonogaki K., Ohba Y., Wakameda M., Tamari T. Fluvoxamine exerts anorexic effect in 5-HT2C receptor mutant mice with heterozygous mutation of beta-endorphin gene. Int J Neuropsychopharmacol 2009, 12:547-552.
6. Nonogaki K., Kaji T. Hypothalamic orexin and pro-opiomelanocortin activities are essential for the anorexic effects of m-chlorophenylpiperazine in mice. Int J Neuropsychopharmacol 2010, 13:1261-1267.
7. Beatie D.T., Simith J.A.M. Serotonin pharmacology in gastrointestinal tract: a review. Naunyn Schmiedebergs Arch Pharmacol 2008, 377:181-203.
8. Lee M.J., Choi S., Im W. 5-HT4 Receptor agonists in the treatment of gastrointestinal motility disorders: current status and perspective. Int J Gastroenterol Disord Ther 2014, 1:108.
9. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2005, 5:262-269.
10. Jarvis C.I., Cabrera A., Charron D. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Ann Pharmacother 2013, 47:1532-1539.
11. Morita Y., Takeuchi K., Asakawa T., Kataoka O., Odaka H. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β-cell function in db/db mice. Br J Pharmacol 2009, 157:415-426.
12. Nonogaki K., Hazama M., Satoh N. Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice. Biomed Res Int 2014, 2014:751930.